Novo Nordisk's Rybelsus Reduces Cardiovascular Risks

Novo Nordisk's oral semaglutide, branded as Rybelsus, has demonstrated a 14% reduction in the risk of major adverse cardiovascular events (MACE) among adults with type 2 diabetes and pre-existing cardiovascular or chronic kidney diseases, according to the SOUL trial results. The study, which enrolled 9,650 participants, compared Rybelsus to a placebo and achieved its primary objective of reducing risks of cardiovascular death, non-fatal heart attacks, and strokes. Novo Nordisk plans to seek regulatory approval for an expanded label for Rybelsus in the U.S. and EU by early next year, with detailed trial results expected to be presented at a scientific conference in 2025. The safety profile of the drug was consistent with previous studies, showing it to be well-tolerated. This trial highlights the importance of effective treatments for the approximately one-third of diabetic patients who also have cardiovascular disease. Novo Nordisk's semaglutide-based drugs have already received regulatory backing for their additional health benefits.